ABT-494 effective for patients with rheumatoid arthritis

December 1, 2016

(HealthDay)—A novel selective JAK-1 inhibitor, ABT-494, is effective for rheumatoid arthritis (RA) patients with inadequate response to methotrexate (MTX) or to at least one anti-tumor necrosis factor (anti-TNF) agent, according to two studies published online Nov. 28 in Arthritis & Rheumatology.

Mark C. Genovese, M.D., from the Stanford University School of Medicine in Palo Alto, Calif., and colleagues examined the safety and efficacy of ABT-494 in 300 with moderate-to-severe RA and an inadequate response to MTX. Participants were randomized to 12 weeks of immediate-release ABT-494 at 3, 6, 12, or 18 mg twice daily, 24 mg once daily, or . The researchers found that the proportion of patients meeting the American College of Rheumatology 20 percent improvement criteria (ACR20) at week 12 was higher with ABT-494 than placebo (62 to 80 percent versus 46 percent).

Joel M. Kremer, M.D., from Albany Medical College in New York, and colleagues compared the efficacy and safety of ABT-494 with placebo in 276 patients with moderate-to-severe RA receiving a stable dose of MTX, with an inadequate response or intolerance to at least one anti-TNF agent. Patients were randomized to receive immediate-release ABT-494 at 3, 6, 12, or 18 mg twice daily or matching placebo. The researchers found that significantly more patients receiving ABT-494 achieved an ACR20 response (53 to 71 percent) versus placebo (34 percent).

"In patients with an inadequate response or intolerance to anti-TNF agents, ABT-494 added to MTX showed rapid, dose-dependent improvements in RA signs and symptoms, with and tolerability similar to those of other drugs of this class," the authors write.

Several authors from both studies disclosed financial ties to pharmaceutical companies, including AbbVie, which manufactures ABT-494 and funded both studies.

Explore further: Non-TNF biologic beats second anti-TNF in rheumatoid arthritis

More information: Full Text - Genovese
Full Text - Kremer

Related Stories

Non-TNF biologic beats second anti-TNF in rheumatoid arthritis

September 21, 2016
(HealthDay)—A non-tumor necrosis factor (TNF)-targeted biologic is more effective than a second anti-TNF drug for treatment of rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug, according ...

Dupilumab effective in atopic dermatitis

October 4, 2016
(HealthDay)—Dupilumab is effective for patients with moderate-to-severe atopic dermatitis that is inadequately controlled by topical treatment, according to a study published online Oct. 1 in the New England Journal of ...

Patients taking certolizumab pegol are twice as likely to achieve ACR20 compared to placebo

June 7, 2012
A new Phase III study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, shows that patients treated with certolizumab pegol (CZP) were twice as likely to meet the primary endpoint ...

Tofacitinib ups rheumatoid arthritis treatment response

August 22, 2013
(HealthDay)—The addition of tofacitinib to rheumatoid arthritis (RA) treatment regimens improves patient response to non-biologic disease-modifying antirheumatic drugs (DMARDs), according to a study published in the Aug. ...

Secukinumab effective in moderate-to-severe psoriasis

July 11, 2014
(HealthDay)—For patients with moderate-to-severe plaque psoriasis, the fully human anti-interleukin-17A monoclonal antibody, secukinumab, is effective, according to research published online July 9 in the New England Journal ...

76 percent of patients on oral JAK1/JAK2 inhibitor plus DMARDS achieve ACR20 response at week 12

June 8, 2012
Data from a Phase IIb study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, show that 76% of patients with active rheumatoid arthritis (RA) receiving either 4mg or 8mg of baricitinib, ...

Recommended for you

Osteoarthritis could be treated as two diseases, scientists reveal

January 10, 2018
Scientists at The University of Manchester have discovered that most people with osteoarthritis can be subdivided into two distinct disease groups, with implications for diagnosis and drug development.

US arthritis prevalence is much higher than current estimates

November 27, 2017
New research indicates that the prevalence of arthritis in the United States has been substantially underestimated, especially among adults

Maintaining sufficient vitamin D levels may help to prevent rheumatoid arthritis

November 20, 2017
Maintaining sufficient vitamin D levels may help to prevent the onset of inflammatory diseases like rheumatoid arthritis, research led by the University of Birmingham has discovered.

Old World monkeys could be key to a new, powerful rheumatoid arthritis therapy

November 16, 2017
In the quest for a new and more effective treatment for rheumatoid arthritis, researchers from the Keck School of Medicine of USC looked to a primate that mostly roams the land in Asia, the Middle East and Africa. It was ...

Study lists foods for fighting rheumatoid arthritis symptoms and progression

November 8, 2017
A list of food items with proven beneficial effects on the progression and symptoms of rheumatoid arthritis is provided in a new study published today in Frontiers in Nutrition. The authors suggest incorporating these foods ...

Prototype equipment can detect rheumatoid arthritis

September 28, 2017
According to a first clinical study published in the scientific journal Photoacoustics, the University of Twente and various European partners have designed a device that shows the difference between healthy fingers and arthritic ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.